Phase 4
N=421
Pain Increases After Shoulder Injection
Shoulder Pain
Bottom Line
View on ClinicalTrials.gov: NCT05438277 ↗Enrolled (actual)
421
Serious AEs
—
Results posted
Mar 2023
Primary outcome: Primary: Incidence of a Flare Reaction — 44; 8; 149; 191 Person-visits
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 4
- Interventions
- Methylprednisolone (MPA) (Drug); Triamcinolone Acetonide (TA) (Drug)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Campbell Clinic
- Primary completion
- Aug 2022
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Incidence of a Flare Reaction |
44; 8; 149; 191; 16; 28 | — |
Summary
Compare FLARE reactions (increase in VAS by two or more points) in the first 48 hours following a shoulder injection.
Eligibility Criteria
Inclusion Criteria
- Subacromial or glenohumeral shoulder pain to be treated with steroid injection
- Fluent in written and oral English
- Willing and able to provide written consent
- Willing to complete follow up pain scores (visual analog score)
Exclusion Criteria
- Unable to provide written consent
- Chronic pain syndrome
- Unwilling to complete follow up pain scores (visual analog score)
Data sourced from ClinicalTrials.gov (NCT05438277). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.